ReviewAmerican journal of clinical dermatology2024
Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options.
Review in American journal of clinical dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris-A systematic review.Frontiers in medicine · 2025Pooled it
- Altered circRNAs: a novel potential mechanism for the functions of extracellular vesicles derived from platelet-rich plasma.Frontiers in bioinformatics · 2025Pooled it
- Tyrosine Kinase 2 Inhibition for Refractory Pityriasis Rubra Pilaris in Two Cases.International journal of dermatology · 2026Article
- Prostate adenocarcinoma in HIV-associated type 6 pityriasis rubra pilaris: A case report.JAAD case reports · 2026Article
- [Erythroderma: etiology, diagnosis, and management-an overview].Dermatologie (Heidelberg, Germany) · 2026Review
- Facial Discoid Dermatosis Imaging with Line-Field Confocal Optical Coherence Tomography and Reflectance Confocal Microscopy-A Case Report and Literature Review.Journal of personalized medicine · 2026Review
- Familial CARD14-associated papulosquamous eruption with a novel mutation successfully treated with secukinumab.JAAD case reports · 2026Article
- Successful treatment of refractory classic juvenile pityriasis rubra pilaris with adalimumab in a 4-year-old girl: a case report.Frontiers in immunology · 2026Article
- Article
- A Child with Bilaterally Symmetrical Papulosquamous Lesions.Indian dermatology online journal · 2025Article
- Regressed anterior mediastinal nodule secondary to removal of dental crowns.Journal of surgical case reports · 2025Article
- Tofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris-A Case Report.Clinical case reports · 2025Article
- Refractory pityriasis rubra pilaris treated with abrocitinib.Dermatology reports · 2025Article
- Psoriasis.Nature reviews. Disease primers · 2025Review
- Pityriasis Rubra Pilaris Following COVID-19 Infection: A Case of Successful Treatment With Ixekizumab.Cureus · 2025Article
- Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments.American journal of clinical dermatology · 2024Review
- Article
- Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris.Life (Basel, Switzerland) · 2024Review
- Severe pityriasis rubra pilaris complicated with Kaposi's varicelliform eruption and cutaneous MRSA infection case report.Heliyon · 2024Article
- Long-Standing Remission After Tildrakizumab Treatment in a Case of Refractory Type I Pityriasis Rubra Pilaris in a Breast Cancer Patient.Clinical, cosmetic and investigational dermatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pityriasis rubra pilaris (PRP) is a rare papulosquamous reaction pattern with a significant impact on quality of life. Type I PRP is the most common PRP variant, presenting as erythematous papules emerging in a follicular distribution and later coalescing into plaques with characteristic islands of sparing; histologically, an alternating pattern of orthokeratosis and parakeratosis is considered the hallmark of PRP (checkerboard hyperkeratosis). Other PRP variants (types II-V) differ in their age of onset and clinical presentation. Type VI PRP is a rare PRP subtype associated with human immunodeficiency virus infection and is occasionally associated with diseases of the follicular occlusion tetrad. Caspase recruitment domain family, member 14 (CARD14)-associated papulosquamous eruption and facial discoid dermatitis are newly described disease states that have an important clinical overlap with PRP, creating shared conundrums with respect to diagnosis and treatment. The etiology inciting PRP often remains uncertain; PRP has been suggested to be associated with infection, malignancy, or drug/vaccine administration in some cases, although these are based on case reports and causality has not been established. Type V PRP is often due to inborn CARD14 mutations. Furthermore, recent literature has identified interleukin-23/T-helper-17 cell axis dysregulation to be a major mediator of PRP pathogenesis, paving the way for mechanism-directed therapy. At present, high-dose isotretinoin, ixekizumab, and secukinumab are systemic agents supported by single-arm prospective studies; numerous other agents have also been trialed for PRP, with variable success rates. Here, we discuss updates on clinical manifestations, present new insights into etiopathogenesis, and offer a survey of recently described therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.